The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: A randomized placebo-controlled trial

Chest

Volumn 142, Issue 1, 2012, Pages 119-127

  Hanania, Nicola A ^a   Feldman, Gregory ^b   Zachgo, Wolfgang ^c   Shim, Jae Jeong ^d   Crim, Courtney ^e   Sanford, Lisa ^f   Lettis, Sally ^f   Barnhart, Frank ^e   Haumann, Brett ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b S Carolina Pharmaceutical Research   (United States)

^c Pneumologisches Forschungsinstitut Hohegeest   (Germany)

^d Korea University College of Medicine   (South Korea)

^e GLAXOSMITHKLINE   (United States)

^f GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; GLUCOSE; PLACEBO; POTASSIUM; VILANTEROL TRIFENATATE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AORTA ANEURYSM; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD PRESSURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERKALEMIA; INTENTION TO TREAT ANALYSIS; LABORATORY TEST; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NOSE CONGESTION; OROPHARYNX PAIN; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; PULSE RATE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SYNCOPE; TREMOR; VITAL SIGN;

EID: 84858957208     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2231     Document Type: Article

References (12)

1. Global Initiative for Chronic Obstructive Lung Disease guideline: global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2009) . Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd.com/. Accessed April 13, 2011.
2. Cazzola M, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol. 2008;155(3):291-299.
3. 2 -agonist (LABA) with rapid onset and long duration, on isolated large and small human airways [abstract]. Am J Respir Crit Care Med. 2010;181:A4453.
4. Ford A, Hughes S, Morrison V, Barrett V, Knowles R. In vitro and in vivo pharmacological characterisation of GW642444, a novel long-acting β2 agonist (LABA), with fast onset and long duration in the guinea-pig [abstract]. Am J Respir Crit Care Med. 2010;181:A5677.
5. 2-agonist (LABA) using human recombinant β1/2/3 adrenoceptor cAMP assays [abstract]. Am J Respir Crit Care Med. 2010;181 :A4451.
6. Kempsford RD, Norris V, Siederer SK. The pharmacodynamics, pharmacokinetics and tolerability of repeat doses of the novel inhaled long-acting β 2 adrenoceptor agonist (LABA) GW642444 (25, 50 and 100mcg) in healthy subjects [abstract]. Am J Respir Crit Care Med. 2010;181:A4461.
7. Kempsford RD, Norris V, Siederer SK. GW642444, a novel inhaled long-acting beta2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100mcg, is well tolerated and demonstrates prolonged bronchodilation in COPD subjects [abstract]. Am J Respir Crit Care Med. 2010;181:A4447.
8. Lötvall J, Bateman ED, Bleecker ER, et al. Dose-related efficacy of vilanterol trifenatate (VI), a long-acting beta2 agonist (LABA) with inherent 24-hour activity, in subjects with persistent asthma [abstract]. Eur Respir J. 2010;36(suppl 54):1013s.
9. Hanania NA, Feldman G, Zachgo W, et al. Dose-related efficacy of vilanterol trifenatate (VI) in COPD [abstract]. Eur Respir J. 2010;36(suppl 54):217s.
10. Hanania NA, Feldman G, Zachgo W, et al. Safety of vilanterol trifenatate (VI) in a COPD dose-ranging study [abstract]. Eur Respir J. 2010;36(suppl 54):208s.
11. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111-124. (Pubitemid 40776231)
12. Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(2):205-215. (Pubitemid 352037881)